Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.
A study evaluating patient vs clinician reports of adverse events reveals which measures provide a more accurate perspective on patient quality of life.
Researchers investigated whether bleomycin posed concerns regarding pulmonary or operative outcomes following PC-RPLND in men treated with chemotherapy for IGCCCG good-risk germ cell cancers.
Researchers presented results of a project designed to reduce opioid use while effectively managing pain and anxiety in patients who had undergone surgery for urologic cancer at the 2018 ASCO Quality Care Symposium.
A review and meta-analysis evaluated the association between metformin use and bladder cancer incidence and various prognostic measures, such as PFS and OS.
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.
Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.